Global health programs need to address community needs

A "key problem" in reaching the goal of polio elimination "may well be that organizers of the global anti-polio initiative, and of other global health programs, are not listening to the people they want to help -- or to each other," Thomas Abraham, an associate professor in the Journalism and Media Studies Center at the University of Hong Kong, writes in a New York Times opinion piece. "As a result, in many communities targeted by [polio immunization] programs, people perceive a gulf between global programs like polio eradication and more immediate local health needs," he continues, adding, "It is cold comfort to save a child from polio if the child later succumbs to malaria or diarrhea from dirty drinking water."

Related Stories

"This raises the question of why global health programs are fragmented along disease-specific lines, rather than addressing multiple diseases and helping to strengthen basic health services," Abraham writes. Because most money "is earmarked for specific health issues" and programs "are required to meet specific targets," it "makes integration, or even cooperation, difficult," he continues. The "top-down" nature of global health programs, whereby donors "call the shots," "is too often devoid of consultation or input from the people who are supposed to benefit from these programs," he says, adding, "The fault largely lies with developing country governments that are often content to accept whatever donors propose rather than try to set their own agenda." Abraham concludes, "Global health programs need to be rebuilt from the bottom up, responding to the most urgent needs of communities, rather than what donors feel they want to fund" (11/19).

This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Leveraging the mass production benefit that MultiBrain® technology brings to neurohistology, NSA can accelerate the R&D preclinical and safety assessment processes many fold and perform them less expensively. This results in faster times for a potential drug to move from R&D to clinical trials and sooner for use in people.

Pittcon is an analytical conference, so naturally my talk will be about analytical chemistry and how analytical chemistry will become increasingly important in delivering healthcare solutions, not only for rich people, but also, hopefully, for poor people across the world.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.